scholarly journals Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide Vasopressin V2-Receptor Antagonist

2006 ◽  
Vol 1 (6) ◽  
pp. 1154-1160 ◽  
Author(s):  
Alain Soupart ◽  
Peter Gross ◽  
Jean-Jacques Legros ◽  
Sándor Alföldi ◽  
Djillali Annane ◽  
...  
Keyword(s):  
Hormone Secretion ◽  
Term Treatment ◽  
Inappropriate Antidiuretic Hormone Secretion ◽  
Antidiuretic Hormone Secretion ◽  
Long Term Treatment ◽  
V2 Receptor ◽  
Vasopressin V2 Receptor Antagonist ◽  
Orally Active ◽  
V2 Receptor Antagonist

Aquaretic and hormonal effects of a vasopressin V2 receptor antagonist after acute and long-term treatment in rats

2000 ◽  
Vol 394 (1) ◽  
pp. 131-138 ◽  
Author(s):  
Colette Lacour ◽  
Gérard Galindo ◽  
Françoise Canals ◽  
Danielle Segondy ◽  
Catherine Cazaubon ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Term Treatment ◽  
Hormonal Effects ◽  
Vasopressin V2 Receptor ◽  
Long Term Treatment ◽  
V2 Receptor ◽  
Vasopressin V2 Receptor Antagonist ◽  
V2 Receptor Antagonist

scholarly journals Review of Tolvaptan in the Treatment of Hyponatremia

2011 ◽  
Vol 3 ◽  
pp. CMT.S4884 ◽  
Author(s):  
Amarinder S. Garcha ◽  
Apurv Khanna
Keyword(s):  
Survival Benefit ◽  
Independent Predictor ◽  
Hormone Secretion ◽  
Short Term ◽  
Significant Independent Predictor ◽  
Term Survival ◽  
Inappropriate Antidiuretic Hormone Secretion ◽  
Electrolyte Disorder ◽  
Antidiuretic Hormone Secretion

Hyponatremia is a very common electrolyte disorder and is a significant independent predictor of medical prognosis and costs. Tolvaptan is a vasopressin receptor antagonist developed for the treatment of hyponatremia. It has its principal application in the treatment of euvolemic and hypervolemic hyponatremia. Its major role is in the treatment of heart failure (HF), cirrhosis and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). While at present tolvaptan has not demonstrated long term survival benefit with its use, it clearly has proven short term efficacy in the management of hyponatremia by demonstrating improvement in serum sodium levels at an acceptable rate without evidence of over-correction.

Long-Term Treatment of Hypertension in Man by an Orally Active Angiotensin-Converting Enzyme Inhibitor

1978 ◽  
Vol 55 (s4) ◽  
pp. 293s-295s ◽  
Author(s):  
H. R. Brunner ◽  
H. Gavras ◽  
G. A. Turini ◽  
B. Waeber ◽  
P. Chappuis ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Enzyme Inhibitor ◽  
Plasma Renin ◽  
Term Treatment ◽  
Hypertensive Patients ◽  
Long Term Treatment ◽  
Treatment Of Hypertension ◽  
Term Administration ◽  
Orally Active

1. Captopril or SQ 14 225, administered orally twice a day, reduced the blood pressure of hypertensive patients whatever their clinical diagnosis and even when their plasma renin activity was ‘normal’ or low. 2. Long-term administration of captopril, either alone or together with diuretics, provides a powerful new tool with which to treat ambulatory hypertensive patients. 3. The renin system may play an important role in maintaining blood pressure in a majority of hypertensive patients.

Sign in / Sign up

Export Citation Format

Share Document